Colivelin TFA,99.22%

产品编号:Bellancom-P1061A| 分子式:C119H206N32O35.C2HF3O2| 分子量:2759.12

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-P1061A
2280.00 杭州 北京(现货)
Bellancom-P1061A
3480.00 杭州 北京(现货)
Bellancom-P1061A
9750.00 杭州 北京(现货)
Bellancom-P1061A
15000.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

Colivelin TFA

产品介绍 Colivelin TFA 是一种具有大脑通透性的神经保护肽 (neuroprotective peptide),是 STAT3 的有效激活剂。Coliveli 通过激活 STAT3 在体外抑制神经元死亡。Colivelin TFA 对神经毒性、Aβ 沉积,神经元细胞凋亡,在神经退行性疾病显示出长期有利的影响。Colivelin TFA 可用于阿尔茨海默病和缺血性脑损伤的相关研究。
生物活性

Colivelin TFA is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro. Colivelin TFA exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease. Colivelin TFA has the potential for the treatment of alzheimer's disease and ischemic brain injury.

体外研究

Colivelin completely suppresses death induced by overexpressed FAD-causative genes and Aβ1-43 at a concentration of 100 fm, and keep its neuroprotective action at or above the levels of 1 nm.
Colivelin-induced neuroprotection occurs via two neuroprotective pathways: one mediated by Ca2+/calmodulin-dependent protein kinase IV, triggered by ADNF, and one mediated by signal transducer and activator of transcription 3, triggered by HN.
Colivelin reverses caspase3, Bax and Bcl-2 expressions in HT22 cells medaited by rmMFG-E8 in the co-cultured cells under OGD condition[4].
Colivelin (50 µg/mL, 4 hours) significantly increases the p-STAT3 protein levels in BV-2 cells[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[4]

Cell Line: BV-2 cells.
Concentration: 50 µg/mL.
Incubation Time: 4 hours.
Result: Increased p-STAT3 levels.

Cell Viability Assay[5]

Cell Line: KYSE70 and TE8 cells.
Concentration: 0.5 μM.
Incubation Time: 1 hour (followed by CYT-Rx20 treatment)
Result: Significantly suppressed the viability in KYSE70 and TE8 cells.
体内研究
(In Vivo)

Colivelin(intracerebroventricular administration; 10 pmol/3 μl; 3 weeks) suppresses impairment in spatial working memory induced by repetitive intracerebroventricular injection of Aβ25-35 or Aβ1-42, in addition, it antagonizes neuronal loss in the CA1 region of hippocampus induced by hippocampal injection of Aβ1-42.
Colivelin (intraperitoneal administration; 1.4, 7, or 35 nM/0.21mL; on the Y-maze testday) suppresses memory impairment caused by 3-quinuclidinyl benzilateand restricts functional memory deficit.
Colivelin (intraperitoneal injection; 1 mg/kg; 14 days) results in improved motor and cognitive function with time by performance of mNSS, rotarod, and corner turning test.It also reduces lesion volume and improves neurological deficits after MCAO.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CD-1 mice
Dosage: 10 pmol/3 μl
Administration: Intracerebroventricular administration
Result: Completely suppressed Aβ 25-35-mediated impairment in spatial working memory and increased the number of immunoreactive neurons.
Animal Model: C57 mice
Dosage: 1.4, 7, or 35 nM/0.21mL
Administration: Intraperitoneal administration
Result: Protected against cholinotoxin-induced amnesia in mice.
Animal Model: Male C57BL/6 mice
Dosage: 1 mg/kg
Administration: Intraperitoneal administration
Result: Protected against ischemic brain injury, and improves neurological outcomes.
体内研究

Colivelin(intracerebroventricular administration; 10 pmol/3 μl; 3 weeks) suppresses impairment in spatial working memory induced by repetitive intracerebroventricular injection of Aβ25-35 or Aβ1-42, in addition, it antagonizes neuronal loss in the CA1 region of hippocampus induced by hippocampal injection of Aβ1-42.
Colivelin (intraperitoneal administration; 1.4, 7, or 35 nM/0.21mL; on the Y-maze testday) suppresses memory impairment caused by 3-quinuclidinyl benzilateand restricts functional memory deficit.
Colivelin (intraperitoneal injection; 1 mg/kg; 14 days) results in improved motor and cognitive function with time by performance of mNSS, rotarod, and corner turning test.It also reduces lesion volume and improves neurological deficits after MCAO.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CD-1 mice
Dosage: 10 pmol/3 μl
Administration: Intracerebroventricular administration
Result: Completely suppressed Aβ 25-35-mediated impairment in spatial working memory and increased the number of immunoreactive neurons.
Animal Model: C57 mice
Dosage: 1.4, 7, or 35 nM/0.21mL
Administration: Intraperitoneal administration
Result: Protected against cholinotoxin-induced amnesia in mice.
Animal Model: Male C57BL/6 mice
Dosage: 1 mg/kg
Administration: Intraperitoneal administration
Result: Protected against ischemic brain injury, and improves neurological outcomes.
体内研究

Colivelin(intracerebroventricular administration; 10 pmol/3 μl; 3 weeks) suppresses impairment in spatial working memory induced by repetitive intracerebroventricular injection of Aβ25-35 or Aβ1-42, in addition, it antagonizes neuronal loss in the CA1 region of hippocampus induced by hippocampal injection of Aβ1-42.
Colivelin (intraperitoneal administration; 1.4, 7, or 35 nM/0.21mL; on the Y-maze testday) suppresses memory impairment caused by 3-quinuclidinyl benzilateand restricts functional memory deficit.
Colivelin (intraperitoneal injection; 1 mg/kg; 14 days) results in improved motor and cognitive function with time by performance of mNSS, rotarod, and corner turning test.It also reduces lesion volume and improves neurological deficits after MCAO.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CD-1 mice
Dosage: 10 pmol/3 μl
Administration: Intracerebroventricular administration
Result: Completely suppressed Aβ 25-35-mediated impairment in spatial working memory and increased the number of immunoreactive neurons.
Animal Model: C57 mice
Dosage: 1.4, 7, or 35 nM/0.21mL
Administration: Intraperitoneal administration
Result: Protected against cholinotoxin-induced amnesia in mice.
Animal Model: Male C57BL/6 mice
Dosage: 1 mg/kg
Administration: Intraperitoneal administration
Result: Protected against ischemic brain injury, and improves neurological outcomes.
性状Solid
溶解性数据
In Vitro: 

H2O : 50 mg/mL (18.12 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.3624 mL 1.8122 mL 3.6243 mL
5 mM 0.0725 mL 0.3624 mL 0.7249 mL
10 mM 0.0362 mL 0.1812 mL 0.3624 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: Water with 5% sefsol and 20% isopropanol

    Solubility: 6.25 mg/mL (2.27 mM); Suspended solution; Need ultrasonic

*以上所有助溶剂都可在 西域 网站选购。
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


服务热线

13911702513
18601927057

微信客服